Home Microbial Fermentation Services pAVEway™ Microbial Expression Platform

pAVEway™ Microbial Expression Platform

pAVEway™ is an efficient microbial protein expression and scale-up platform

pAVEway™ is a proven and innovative technology platform for the efficient microbial expression of proteins based on E.coli. The system offers industry-leading titers with proven scalability in more than one hundred projects over the last decade. Time to first clinical manufacture and strain generation has been reduced from six to four weeks, through ambr^™ 250 technology.

Antibiotic-free fermentation ensures low regulatory risk without the loss of yield or versatility. And the class leading fermentation productivity ensures high yield recombinant protein production for a wide range of targets.

pAVEway™ offers efficient expression for a wide range of biotherapeutic proteins, through a variety of accumulation routes; intracellular soluble, intracellular insoluble, and periplasmic secretion. The optimal route can be tailored for each individual protein.

Platform description

Host cells

Available host cells include a panel of E.coli host cells. The cell lines were selected for their ability to express recombinant proteins with great efficiency and because of their robust fermentation performance at high cell densities.

Fast track process definition

Rapid entry into first clinical manufacture is accomplished by the integrated use ambr™250 technologies to achieve strain generation in four weeks.

Unique protein vectors and expression controls

pAVEway™ expression is based on unique protein vectors that are designed to maintain transcription control via DNA looping. Modulation of expression is based on level of inducer added. The technology allows for the manipulation of induction conditions to optimize accumulation allowing for maximization of protein expression as either inclusion bodies, cytoplasmic soluble or periplasmic secretion.

Batch feed and induction protocols

pAVEway™ is based on batch medium with a pre-developed feed strategy that delivers high ‘protein productive’ biomass levels – with proven scalability. Induction protocols are pre-developed, no matter how the protein is expressed:

Inclusion body formation
Soluble intracellular accumulation
Secretion – periplasmic/growth medium

BENIFITS

Industry leading titers

High producing E.coli strains selected Highly efficient expression of recombinant proteins Robust fermentation performance at high cell densities.

Speed

Fast track process creation and development with integrated ambr™ Reduced time to clinic – reduced time to market Strain generation reduced from six to four weeks

Cost efficiency

High yield protein production through class leading fermentation productivity, with potential for reduced cost of goods

Regulatory

Antibiotic-free cGMP large-scale manufacturing with high yield and versatility

Flexibility

Wide range of biotherapeutic proteins and accumulation routes: intracellular soluble, intracellular insoluble, and periplasmic secretionProven scalability

Suitable for large-scale manufacture – over 100 different therapeutic proteins produced at very high titers over the past decade

Rapid and scalable upstream process development with ambr® 250

High-throughput design and analysis tools ensure rapid, scalable upstream process development. Workflow is accelerated by automated screening for specificity and productivity using integrated ambr™ 250 technology. By implementing the ambr™250 technologies we have reduced strain generation from six to four weeks.